ACIP Recommendations

The ACIP develops recommendations on how to use vaccines to control disease in the United States.

The Committee’s recommendations are forwarded to CDC’s Director for approval. Once the ACIP recommendations have been reviewed and approved by the CDC Director and the U.S. Department of Health and Human Services, they are published in CDC’s Morbidity and Mortality Weekly Report (MMWR). The MMWR publication represents the final and official CDC recommendations for immunization of the U.S. population.

Professional organizations that work with the ACIP to develop the annual childhood and adult schedules include the American Academy of Pediatrics (AAP), the American Academy of Family Physicians (AAFP), the American College of Obstetricians and Gynecologists (ACOG), and the American College of Physicians (ACP).

  • ACIP Recommendations
    Complete list of ACIP recommendations published in the MMWR.
  • Immunization Schedules
    Links to the childhood, adolescent, catch-up, and adult immunization schedules; plus vaccine recording and screening forms.
June 2019 Meeting Recommendations

ACIP approved the following recommendations by majority vote at its June 2019 meeting:

  • Human Papillomavirus (HPV) Vaccine
    • ACIP recommends catch-up vaccination for persons through age 26 years who are not adequately vaccinated
    • ACIP recommends vaccination based on shared clinical decision making for individuals aged 27 through 45 years who are not adequately vaccinated. HPV vaccines are not licensed for use in adults older than age 45 years
  • Pneumococcal Vaccines
    • ACIP recommends PCV13 based on shared clinical decision making for adults 65 years or older who do not have an immunocompromising condition and who have not previously received PCV13. All adults 65 years or older should receive a dose of PPSV23.
  • Influenza Vaccines
    • ACIP recommends annual influenza vaccination is recommended for all persons aged 6 months and older who do not have contraindications.
  • Hepatitis A Vaccines
    • ACIP recommends that all children and adolescents aged 2 through 18 years who have not previously received Hepatitis A vaccine be vaccinated routinely at any age (i.e., children and adolescents are recommended for catch-up vaccination).
    • ACIP recommends all persons with HIV aged ≥1 year be routinely vaccinated with Hepatitis A vaccine.
  • Serogroup B Meningococcal (MenB) Vaccines
    • For persons aged ≥10 years with complement deficiency, complement inhibitor use, asplenia, or who are microbiologists:
      • ACIP recommends a MenB booster dose 1 year following completion of a MenB primary series followed by MenB booster doses every 2-3 years thereafter, for as long as increased risk remains.
    • For persons aged ≥10 years determined by public health officials to be at increased risk during an outbreak:
      • ACIP recommends a one-time booster dose if it has been ≥1 year since completion of a MenB primary series.
      • A booster dose interval of ≥6 months may be considered by public health officials depending on the specific outbreak, vaccination strategy, and projected duration of elevated risk.

These recommendations have been adopted by the CDC Director and will become official once published in MMWR.

February 2019 Meeting Recommendations

ACIP approved the following recommendations by majority vote at its February 2019 meeting:

  • Japanese encephalitis (JE) vaccine
    • JE vaccine is recommended for persons moving to a JE-endemic country to take up residence, longer-term (e.g., ≥1 month) travelers to JE-endemic areas, and frequent travelers to JE-endemic areas. JE vaccine also should be considered for shorter-term (e.g., <1 month) travelers with an increased risk of JE based on planned travel duration, season, location, activities, and accommodations. Vaccination also should be considered for travelers to endemic areas who are uncertain of specific duration of travel, destinations, or activities. JE vaccine is not recommended for travelers with very low risk itineraries, such as shorter-term travel limited to urban areas or travel that occurs outside of a well-defined JE virus transmission season.
    • In adults aged 18–65 years, the primary vaccination schedule is two doses administered on days 0 and 7–28.
    • For adults and children, a booster dose (i.e., third dose)  should be given at ≥1 year after completion of the primary JE-VC series if ongoing exposure or re-exposure to JE virus is expected.
  • Anthrax Vaccine
    • A booster dose of AVA may be given every 3 years to persons not currently at high-risk of exposure to B. anthracis who have been previously primed with AVA and wish to maintain protection.

These recommendations have been adopted by the CDC Director and will become official once published in MMWR.

June 2018 Meeting Recommendations

ACIP approved the following recommendations by majority vote at its June 2018 meeting:

  • Reaffirmed the seasonal influenza recommendations for the 2018-2019 influenza season
  • Anthrax vaccine use for post-exposure prophylaxis in a mass vaccination campaign, including:
    • The intramuscular route of administration may be used if the subcutaneous route of administration presents clinical, operational, or logistical challenges that may delay or prevent effective vaccination
    • Should there be an inadequate supply of anthrax vaccine available for post-exposure prophylaxis, either 2 full doses or 3 half doses of anthrax vaccine absorbed (AVA) may be used to expand vaccine coverage
    • In immunocompetent adults aged 18 through 65 years, antimicrobials given in conjunction with vaccine may be discontinued at 42 days after the first vaccine dose or 2 weeks after the last vaccine dose, whichever comes later

These recommendations have been adopted by the CDC Director and will become official once published in MMWR.

Page last reviewed: March 21, 2019